AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03476018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Z-100
Description: Twice a week until 29 days after completion of chemoradiotherapy, then once every 14 days
Study NCT03476018 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Twice a week until 29 days after completion of chemoradiotherapy, then once every 14 days
Study NCT03067896 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Patients will receive intrathecal hyperbaric bupivacaine 12.5 mg in 2.5 ml
Study NCT03844412 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5% lidocaine/5 mg/ml 0.02% estradiol compound cream
Description: Lidocaine/estradiol cream targets peripheral nerves and tissues affected in VBD. Participants will be provided with a diagram and written instructions, detailing how to apply the cream to the vaginal vestibule daily for weeks 1-16. Treatment with lidocaine/estradiol or placebo cream will be terminated at week 16 (end of month 4).
Study NCT03844412 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nortriptyline
Description: Nortriptyline is a centrally-acting tricyclic antidepressant that is FDA-approved for treatment of neuropathic pain. Dosing will begin with one 10 mg pill nightly for week 1, then two 10 mg pills nightly for week 2, three 10 mg pills nightly for week 3, four 10 mg pills nightly for week 4, and five for weeks 5 -16. Treatment with nortriptyline or placebo pill will be tapered off over weeks 16-18, decreasing the dose by 10 mg every 4 days. Participants will be provided with a list of drugs to avoid that are known to interact with nortriptyline.
Study NCT03637127 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Simulated Altitude (FiO2: 15.1%)
Description: Inhalation of deoxygenated air through a altitude simulator (Altitrainer), for approx. 1 hour. given by a facemask.
Study NCT03637127 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shamed Hypoxia (FiO2: 20.9)
Description: Inhalation of unmodified air through an altitude Simulator (Altitrainer) for approximately 1 hour given by a facemask
Study NCT04211480 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: γ-globin reactivated autologous hematopoietic stem cells
Description: gene edited autologous hematopoietic stem cells with γ-globin expression
Study NCT00766493 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GORE® Embolic Filter
Description: Embolic protection during carotid stenting
Study NCT05337969 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin and Vildagliptin 850/50 mg
Description: 50 mg Vildagliptin + 850 mg Metformin as single-dose per study period
Study NCT05337969 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin and Vildagliptin 850/50 mg
Description: 50 mg Vildagliptin + 850 mg Metformin as single-dose per study period
Study NCT02403674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doravirine, Tenofovir, Lamivudine
Description: One doravirine, tenofovir, lamivudine tablet taken q.d. by mouth.
Study NCT02403674 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ATRIPLA™
Description: One ATRIPLA™ tablet taken q.d. by mouth
Study NCT02403674 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo tablets matched to ATRIPLA® or Doravirine, Tenofovir, Lamivudine.
Study NCT02403674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets matched to ATRIPLA® or Doravirine, Tenofovir, Lamivudine.
Study NCT03844412 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo cream
Description: The comparison treatment will be an identical-appearing placebo Moisturel™ cream
Study NCT03844412 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo cream
Description: The comparison treatment will be an identical-appearing placebo Moisturel™ cream
Study NCT01551589 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Involved Field Irradiation(IFI)
Description: Involved Field Irradiation(IFI):only irradiate positive lymph node by CT or PET-CT Radiation: IMRT IMRT is administered with chemotherapy from week 1 to week 8PTV-GTV（primary tumor）：66-70Gy/33\~35F，once a day, 5 times per week PTV-CTV（Clinical target,primary tumor extended 3cm in Axial）：50-56Gy/33\~35f，once a day, 5 times per week PTV-GTVnd（positive node）：66-70Gy/33\~35F，once a day, 5 times per week.
Study NCT01551589 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel and cisplatin
Description: Drug: docetaxel and cisplatin.Consists of docetaxel 60-80mg/m2 day 1 and cisplatin 25mg/m2 days 1 to 3, repeat every 3 weeks, for 2 cycles.
Study NCT03067896 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Patients will receive intrathecal hyperbaric bupivacaine 10 mg in 2 ml with dexmdetomidine 5 µg in 0.5 ml normal saline
Study NCT03067896 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Sulfate
Description: Patients will receive intrathecal hyperbaric bupivacaine 10 mg in 2 ml magnesium sulfate 50 mg in 0.5 ml normal saline
Study NCT01439529 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Device programming: nominal
Description: CRT device is programmed to nominal values
Study NCT01439529 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Programming optimization by QRS
Description: CRT device is programmed by QRS optimization
Study NCT03695523 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PLAY (PhysicaL ActivitY) Policy Intervention
Description: An evidence-based physical activity policy that was developed by researchers and childcare stakeholders and directed by the Canadian 24-Hour Movement Guidelines for the Early Years will be adopted by experimental group childcare centres for 8 weeks. The policy incorporates 8 items (i.e., encouraging children to engage in higher intensity energetic play often, aiming to accumulate 40 minutes each day, exposing children to a variety of indoor and outdoor physical activities, child-directed and teacher-facilitated active play daily, short bouts of outdoor time for a total of 120 minutes each day made up of primarily unstructured free play, encouraging physical literacy by practicing fundamental movement skills, not exposing children to screen-based technology during childcare, and purposefully breaking up sustained sedentary time using physical activities).
Study NCT01551589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel and cisplatin
Description: Drug: docetaxel and cisplatin.Consists of docetaxel 60-80mg/m2 day 1 and cisplatin 25mg/m2 days 1 to 3, repeat every 3 weeks, for 2 cycles.
Study NCT01551589 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Elective Nodal Irradiation (ENI)
Description: The CTVn of ENI included the involved lymph node regions and clinically uninvolved lymph nodal stations according to the location of primary tumor. Lymph node station numbers 1/2/4/5/7, 2/4/5/7 and 4/5/7/16/17were included for upper, middle and lower thoracic ESCC in the ENI arm respectively.
Study NCT00809432 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Face mask (Dust Respirator)
Description: Subjects to wear a simple face mask for 24 hours prior to the study day and the 24 hours of the study day. They will be instructed to wear the mask as much as possible when indoors and at all times when outdoors.
Study NCT00809432 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No Face mask
Description: Subjects will not wear a face mask to reduce their personal exposure to air pollution
Study NCT01440049 — intervention group
Intervention type: OTHER
Intervention: Prospective Observational
Description: this is an observational study non interventional
Study NCT04547803 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Outpatient appointments and activities including radiologic procedures for discharging patients as standard of practice
Study NCT04547803 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Outpatient appointments and activities including radiologic procedures for discharging patients as standard of practice
Study NCT04547803 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video Visit
Description: 15-20 minute Video visit with an advanced practice provider (nurse practitioner or physician assistant) approximately 2-5 days after discharge.
Study NCT01725867 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PT program
Description: manual myofascial release for craniomandibular system for 30\~40 minutes chin-in exercise within 10 minutes and as home exercise self-care education twice per week for 8 weeks
Study NCT01725867 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: oral appliance
Description: custom-made oral appliance: wear every night for 8 weeks, occasional drop is allowed self-care education
Study NCT03844412 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo pill
Description: The comparison treatment will be an identical-appearing placebo pill
Study NCT03844412 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo pill
Description: The comparison treatment will be an identical-appearing placebo pill
Study NCT00833729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etanercept
Description: 50 mg twice weekly (BIW) for 12 wks followed by a dose reduction to 50mg once weekly (OW) for an additional 12 weeks.
Study NCT04014192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Treated with dapagliflozin 10mg/d for one week.
Study NCT04014192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: Treated with empagliflozin 10mg/d for one week.
Study NCT04014192 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Description: Treated with canagliflozin 100mg/d for one week.
Study NCT01468961 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based CBT
Description: 10 weeks of internet-based CBT with online therapist contact
Study NCT02958072 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LeucoPatch
Description: LeucoPatch is an fully autologous growth factor-containing dressing
Study NCT02958072 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: LeucoPatch
Description: LeucoPatch is an fully autologous growth factor-containing dressing
Study NCT03186378 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: VP-102 with applicator
Description: Subjects will receive treatment to their molluscum contagiosum with VP-102.
Study NCT03931811 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Short wave diathermy
Description: SWD group took short wave diathermy with specifications of 400 watt power output, 27.12 MHz frequency, 11.06m wave length, using condensators and electrodes of 12 cm diameter parallel to the knee for 20 minutes(Enraf-Nonius, Curapuls 970 Short wave diathermy device).
Study NCT03931811 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Prolotherapy
Description: Prolotherapy solutions were injected to the knee by a blinded physician in the group, using 25 gauge needle, with solutions being 6 ml 25 % dextrose (3 ml 20% dextrose + 3 ml 30% dextrose) for intraarticular, and 20 ml 15% dextrose (10 ml 0,9% NaCl + 10 ml 30% dextrose) for periarticular. Injection points wwere defined as medial collateral ligaments, adhesion points of quadriceps tendon, adhesion points of patellar tendon, tuberositas tibia, pes anserinus, lateral collateral ligaments, coronal ligaments, medial and lateral tibia plateaus. Patients were blinded to their treatment groups
Study NCT03191305 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Coumadin
Description: Patients in Coumadin Group would be administered Coumadin with overlap of heparin for first two days followed by Coumadin given orally ,dose being adjusted according to INR .The INR range would be between 2-3.it would be given once a day. The total duration Of coumadin would be six months.
Study NCT02375763 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Software instruction
Study NCT03931811 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prolotherapy
Description: Prolotherapy solutions were injected to the knee by a blinded physician in the group, using 25 gauge needle, with solutions being 6 ml 25 % dextrose (3 ml 20% dextrose + 3 ml 30% dextrose) for intraarticular, and 20 ml 15% dextrose (10 ml 0,9% NaCl + 10 ml 30% dextrose) for periarticular. Injection points wwere defined as medial collateral ligaments, adhesion points of quadriceps tendon, adhesion points of patellar tendon, tuberositas tibia, pes anserinus, lateral collateral ligaments, coronal ligaments, medial and lateral tibia plateaus. Patients were blinded to their treatment groups
Study NCT03191305 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivoroxaban
Description: The dose protocol would be similar to the one used in Deep Venous Thrombosis. 15 mg PO q12hr for 21 days with food, Then 20 mg PO qDay for 6 months.
Study NCT00684554 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine
Description: Dose is determined according to the participants' individual need.
Study NCT04502186 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Raising Our Spirits Together
Description: Raising Our Spirits Together (ROST) is an 8-session computer-assisted cognitive behavioral therapy for depression. Core CBT content, including behavioral activation, cognitive restructuring, and problem solving, are delivered via the computer-assisted platform using video and text-based elements. The computer-assisted intervention is complemented by a workbook that includes in-session exercises as well as homework/action plans. ROST is delivered weekly, either virtually or in-person at a local church, and facilitated by a local pastor.
Study NCT04502186 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Enhanced Control Condition
Description: The Enhanced Control Condition intervention consists of providing participants randomized to this condition with a self-help book for depression (The Depression Helpbook; Katon et al, 2008) that is widely used and found to be beneficial, a local resource guide, and referrals.
Study NCT04221048 — intervention group
Intervention type: OTHER
Intervention: Retrospective observational
Description: Pregnancy scores will be based on information obtained from the relevant clinical letter and clinical notes
Study NCT02375763 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Software instruction
Study NCT04302090 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Regulated expiratory method
Description: This method was originally a postpartum abdomino-perineal rehabilitation technique. It allows a functional abdominal rehabilitation by combining a regulated breath in a specific mouthpiece and an abdominal stimulation triggered by this same breath. The use of this method was extended to labor and childbirth. In fact, the application of the method during labor is based on the use of a flow regulating device (Winner Flow + URO-MG®). By regulating the flow of breath during a uterine contraction, it allows better pain management.
Study NCT02940223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethyl Icosapentate
Description: Given by mouth 2 gm orally daily plus physical activity
Study NCT02940223 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Complete resistance exercises and undergo walking program
Study NCT02940223 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Meet with exercise specialist and complete stretching exercises
Study NCT02940223 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02940223 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Given PO
Study NCT02940223 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT00717418 — intervention group
Intervention type: DRUG
Intervention: cyclosporine ophthalmic emulsion 0.05%, artificial tears
Description: one drop, twice a day in each eye
Study NCT02021500 — intervention group
Intervention type: DRUG
Intervention: ABI-007
Description: No intervention is being given in this extension study which is gathering survival information on participants of study NCT 00844649 (Celgene study CA046) who were known to be alive as of March 2013)
Study NCT00205504 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ortho Tri Cyclen
Description: Ortho Tri Cyclen, one tablet daily, for 6 cycles
Study NCT04635696 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethyl chloride
Description: Pressurized vapocoolant developed for acute, mild pain relief.
Study NCT04635696 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Tissue culture grade water
Description: Pressurized water mist
Study NCT00269386 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin
Description: Clarithromycin S/R 1g once daily April 2004 - Clarithromycin S/R (Klaricid XL) ceased to be abailable and subsequent patients will receive standard Clarithromycin 500mg bd
Study NCT04383977 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib and Etoposide capsule
Description: Apatinib (375 mg qd, q3w) and Etoposide capsule(50 mg/d, d1-14, q3w) combination until disease progression or intolerable toxicity
Study NCT04383977 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apatinib
Description: Apatinib (375 mg qd, q3w) until disease progression or intolerable toxicity
Study NCT00876174 — intervention group
Intervention type: PROCEDURE
Intervention: Blood sampling of peripheral blood mononuclear cells
Description: Group 1, (Patients): PMBC (20 ml blood) to be drawn at baseline, weeks 4 and 12 during antiviral therapy and 24 weeks following the end of antiviral therapy
Study NCT00876174 — intervention group
Intervention type: PROCEDURE
Intervention: Blood draw, 20ml peripheral blood mononuclear cells
Description: One time blood draw of 20 ml
Study NCT02013193 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ranger DCB
Description: After successful pre-dilatation the index lesion is treated with one or two Ranger DCB devices that completely cover the lesion. If two devices are deployed, overlap shall be minimal.
Study NCT02013193 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: uncoated PTA balloon
Description: The index lesion is treated with one or more uncoated standard PTA balloons that completely cover the lesion.
Study NCT02025972 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic umbilical cord blood therapy
Study NCT04151381 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aminophylline
Description: the control group (n =15 ) the patients will receive 20 ml of normal saline IV ,20 minutes before induction of general anesthesia .~Amiopphylline 2mg:(n = 15) the patients will receive 2 mg/kg intravenous (IV) aminophylline diluted in 20 ml normal saline 20 minutes before induction of general anesthesia .~Aminophylline 4mg: (n = 15) the patients will receive 4 mg/kg intravenous (IV) aminophylline diluted in 20 ml normal saline 20 minutes before induction of general anesthesia .The study drugs will be given by an anesthetist unaware of the study protocol.
Study NCT04151381 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aminophylline
Description: the control group (n =15 ) the patients will receive 20 ml of normal saline IV ,20 minutes before induction of general anesthesia .~Amiopphylline 2mg:(n = 15) the patients will receive 2 mg/kg intravenous (IV) aminophylline diluted in 20 ml normal saline 20 minutes before induction of general anesthesia .~Aminophylline 4mg: (n = 15) the patients will receive 4 mg/kg intravenous (IV) aminophylline diluted in 20 ml normal saline 20 minutes before induction of general anesthesia .The study drugs will be given by an anesthetist unaware of the study protocol.
Study NCT04018014 — intervention group
Intervention type: OTHER
Intervention: CT angiography
Description: CT angiography in detection of pulmonary embolism
Study NCT02940223 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02058355 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Consequences List Feedback
Study NCT02058355 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized Normative Feedback
Study NCT00759512 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic Touch
Study NCT04316572 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mental health specialist video consultation
Description: The consultations will be based on a psychodynamic understanding with a solution-oriented stance and will follow a manual:~Session 1: Getting familiar with the telemental health setting, building a working alliance and deepening diagnostics.~Session 2: Clarification of the task/objective, focus building, motivational interviewing if necessary.~Session 3-4: Focused brief interventions e.g. psychoeducation, promotion of social resources, activation of health-promoting lifestyles (sleep hygiene, eating diary, relaxation etc.), work on personal problems and, if necessary, initiation of further specialised treatment.~Session 5: Ending the intervention, stabilisation, subsequent treatment plan and communicating a case summary to the general practitioner
Study NCT01207739 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline
Description: After open-label i.v. ceftriaxone 2000 mg qd via a peripheral i.v. catheter: oral Doxycycline 100 mg combined with a placebo b.i.d. for 12 weeks